Salt Lake City-based Spectrum Health Sciences has named Damon Silvestry as its CEO to lead the growth of SimplyTest, its salivary testing subsidiary serving health care providers. SimplyTest’s flagship product is a saliva COVID-19 test.
Spectrum has also appointed Justin Hunt as president.
With more than 20 years of leadership experience spanning operations, commercial strategy, supply chain and organizational transformation, Silvestry brings a track record of driving growth and efficiency across health and science industries, the company said in a release. Most recently, Silvestry served as chief operating officer at Caelum Diagnostics, a company developing real-time biopsy diagnostics powered by advanced imaging and AI. He has also held executive roles at Progenity, Natera, Caris Life Sciences, Miraca Life Sciences and Ellie Diagnostics.
“I’m honored to lead Spectrum Health Science and SimplyTest at such a pivotal moment,” Silvestry said. “We are advancing accessible, high-quality salivary testing that transforms care in oral health, women’s health and functional health. We are just beginning to unlock the powerful role salivary diagnostics can play in advancing personalized medicine. With this approach, SimplyTest is defining a new standard in preventive and precision care.”
In his new role as president of Spectrum Health Science, Hunt will now focus on broadening the organization’s strategic platform, driving innovation and fostering integration across its expanding portfolio of provider-focused health solutions, the release said.
“Damon is an exceptional leader with a deep understanding of the complexity and opportunity in modern health care services,” Hunt said. “He brings the leadership experience we need to take SimplyTest from a breakthrough innovator to a market leader across multiple diagnostic categories.”
Spectrum Health Science said the leadership transition aligns with its broader strategic initiative to deepen its investment in agile, science-backed technologies that serve frontline providers and their patients. It also underscores the company’s evolution from a commodity manufacturer to a repeatable, scalable platform designed to deliver durable enterprise value.